NN-9828

N/A

Report date: 2024/02/27 20:00:31

Base Information

Drug NameNN-9828
Drug Alias NameNN-8828NNC-0114-0000-0005NNC0114-0006NNC114-0005NN-9828 +[6] 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionInterleukin-21 inhibitors
TargetsInterleukin-21
Therapy Area/IndicationsInflammationDiabetes Mellitus, Type 1Diabetes Mellitus +[6] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBelgiumBulgaria +[24] 
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesBristol-Myers Squibb Company
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesNovo Nordisk A/SAlmirall Sa
Active IndicationsN/A
Inactive IndicationsInflammationDiabetes Mellitus, Type 1Diabetes Mellitus +[6] 

Other Information

ATC CodeN/A
Related LinksN/A